The U.S. Department of Defense-funded TRACK-TBI Precision Medicine stduy will utilize the rich TRACK-TBI dataset to validate biomarkers of diffuse axonal injury (DAI), microvascular injury (MVI), and neuro-inflammation using advanced blood-based assay platforms and MRI sequences. The project will validate early and ultra-early blood-based and imaging biomarkers of DAI, MVI, and neuro-inflammation and will conduct a multicenter, double-blind, placebo-controlled exploratory clinical trial comparing the impact of generic cyclosporine on blood-based and imaging biomarkers of DAI and neuro-inflammation in moderate/severe TBI patients. TRACK-TBI Precision Medicine is currently enrolling at three network sites will additional sites to be activated.
If you are interested in learning more about this study, please see the study on Clinicaltrials.gov